Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Current Deferred Revenue (2017 - 2023)

BeOne Medicines (BEIGF) has disclosed Current Deferred Revenue for 8 consecutive years, with $159.0 million as the latest value for Q2 2023.

  • Quarterly Current Deferred Revenue fell 2.67% to $159.0 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $159.0 million through Jun 2023, down 2.67% year-over-year, with the annual reading at $213.9 million for FY2022, 28.71% down from the prior year.
  • Current Deferred Revenue for Q2 2023 was $159.0 million at BeOne Medicines, down from $185.5 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $300.0 million in Q4 2021, with the low at $17.5 million in Q1 2019.
  • Average Current Deferred Revenue over 4 years is $141.4 million, with a median of $159.0 million recorded in 2023.
  • Peak annual rise in Current Deferred Revenue hit 156.89% in 2022, while the deepest fall reached 28.71% in 2022.
  • Over 4 years, Current Deferred Revenue stood at $17.5 million in 2019, then skyrocketed by 1613.89% to $300.0 million in 2021, then decreased by 28.71% to $213.9 million in 2022, then fell by 25.64% to $159.0 million in 2023.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $159.0 million, $185.5 million, and $213.9 million for Q2 2023, Q1 2023, and Q4 2022 respectively.